February 11th 2025
Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, biomarkers, and other cancer treatments, will be highlighted at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).
February 7th 2025
Watch the series now!
In Oncology, Navigating PBMs Starts With Knowing What’s in the Contract
Panel Discusses the Ongoing Evolution of Remote Patient Care